ERC Einstein-Rockefeller-CUNY Center for AIDS research

ERC 爱因斯坦-洛克菲勒-纽约市立大学艾滋病研究中心

• 批准号: 10458259
• 负责人: HARRIS GOLDSTEIN
• 金额: $ 360.37万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10458259
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Adherence; Affinity; Area; Award; Basic Science; Behavioral; Behavioral Research; Behavioral Sciences; Biological Markers; Centers for Disease Control and Prevention (U.S.); Cities; Clinical; Clinical Research; Clinical Sciences; Collaborations; Communities; Community Health; Country; County; Data; Development; Diagnosis; Economically Deprived Population; Epidemic; Epidemiology; Failure; Financial Support; Funding; Future; Goals; Grant; HIV; HIV Infections; HIV diagnosis; Health; Health system; Immunologic Adjuvants; Implant; Improve Access; Infection; Inflammatory; Infrastructure; Institution; Interdisciplinary Study; Investments; Knowledge; Lead; Leadership; Link; Location; Logistics; Medicine; Mental Health; Mental disorders; Mentors; Modality; National Institute of Mental Health; New York; New York City; Outcome; Paper; Pathogenesis; Patients; Persons; Play; Population; Prevention; Process; Productivity; Prophylactic treatment; Public Health; Public Health Schools; Publications; Publishing; Research; Research Personnel; Research Priority; Resources; Role; Services; Site; Strategic Planning; Technology; Translating; Translational Research; United States; United States National Institutes of Health; Universities; Vacuum; Viral; Viremia; Vision; antiretroviral therapy; base; behavioral study; catalyst; chimeric antigen receptor T cells; clinical center; college; epidemiology study; implementation research; implementation science; implementation strategy; improved; innovation; member; neurochemistry; neutralizing antibody; next generation; novel; novel therapeutics; pandemic disease; pre-exposure prophylaxis; prevent; preventive intervention; programs; recruit; response; scale up; social disadvantage; success; synergism; therapy adherence; transmission process; uptake; working group

PROJECT SUMMARY ERC-CFAR: OVERALL As the HIV research community and public health systems implement the vision of Ending the HIV Epidemic (EHE), Centers for AIDS Research (CFAR) play a crucial role leading the trans-institutional and interdisciplinary research efforts needed to achieve this goal. We successfully filled a vacuum in New York City, a continuing epicenter of HIV infection previously lacking a CFAR, by creating the Einstein-Rockefeller-CUNY CFAR (ERC- CFAR). The ERC-CFAR brings together and synergizes the complementary expertise and resources of researchers from a strong basic and clinical research institution linked to a health system which treats >6,200 people with HIV, the Albert Einstein College of Medicine (Einstein); a globally pre-eminent basic science institution, Rockefeller University (Rockefeller); and a strong public health/implementation science institution, CUNY School of Public Health/Hunter College (CUNY), while establishing linkages to the NYC Department of Health and Mental Hygiene. Our vision is for the ERC-CFAR to serve as a catalyst to create innovation and contribute to EHE by breaking down institutional and disciplinary silos in our complementary basic, translational, clinical, epidemiologic, behavioral, and implementation research programs to accelerate development of new therapies, assess and overcome barriers to acceptability, uptake, and adherence, and prevent and cure HIV infections. The success of the ERC-CFAR Cores, SWGs, and infrastructure in amplifying the research productivity of our three institutions is illustrated by a >30% increase in our OAR FRB from ~$34 million in FY15 to ~$44.6 million in FY20 and the publication of >1,250 papers by ERC-CFAR investigators. Our ESIs obtained ~$20 million of external grant funding, including ~$7.5 million in NIH grants catalyzed by ~$500K we awarded for 14 pilot grants, a >16-fold return on investment. We also integrated the concerns of our community members, including PWH, into our strategic planning process by organizing a novel, highly trans-institutional and interdisciplinary Scientific Working Group (SWG), with greater than 30 members focused on our community’s priority research area, HIV and Mental Health. In this renewal, we propose to build on our accomplishments to further catalyze research to end the epidemic through these Specific Aims: 1) To assemble transinstitutional, interdisciplinary, community-inclusive ERC-CFAR research teams to develop and implement new strategies to reduce HIV transmission, improve prevention and treatment, promote sustained viral suppression, and eradicate HIV reservoirs; 2) To increase the impact of our research through the cutting-edge services of our Biomarkers and Advanced Technologies Core, Behavioral and Implementation Science Core, and Clinical and Translational Science Core; 3) To mentor the next generation of HIV investigators, recruit established non-HIV investigators into HIV research, and forge new collaborations across Einstein, Rockefeller, and CUNY, other NIH-funded centers, regional academic centers, our public health departments, and community partners to support an innovative EHE agenda through the Developmental Core and current HIV & Mental Health and future SWGs.

项目摘要 ERC-CFAR：总体 随着艾滋病毒研究界和公共卫生系统的实施，结束艾滋病毒流行的愿景 （EHE），艾滋病研究中心（CFAR）扮演着至关重要的角色 需要研究这一目标所需的研究工作。我们在纽约市成功填补了一个真空 通过创建Einstein-Rockefeller-Cuny CFAR（ERC-- CFAR）。 ERC-CFAR汇集在一起​​并综合了完善的专业知识和资源 来自强大基础和临床研究机构的研究人员与卫生系统有关，该系统> 6,200 艾滋病毒的人，阿尔伯特·爱因斯坦医学院（爱因斯坦）；全球杰出的基础科学 洛克菲勒大学（Rockefeller）机构；以及强大的公共卫生/实施科学机构， CUNY公共卫生/猎人学院（CUNY），同时建立与纽约市的联系 健康和精神卫生。我们的愿景是让ERC-CFAR作为创新创新和的催化剂 通过在我们的完善基础，翻译， 临床，流行病学，行为和实施研究计划，以加速新的发展 治疗，评估和克服可接受性，摄取和依从性的障碍，并预防和治愈HIV 感染。 ERC-CFAR核心，SWG和基础设施的成功在扩大研究中 我们的三个机构的生产率通过我们的OAR FRB从2015财年的3400万美元提高了3400万美元来说明 到20财年的约4460万美元，以及ERC-CFAR调查人员发表> 1,250篇论文。我们的ESI获得了 〜2000万美元的外部赠款资金，其中包括约750万美元的NIH赠款，我们授予了约50万美元 对于14个飞行员赠款，投资回报率> 16倍。我们还整合了社区成员的关注 包括PWH在内，通过组织一个高度跨国机构和 跨学科科学工作组（SWG），大于30名成员专注于我们社区的 优先研究领域，艾滋病毒和心理健康。在这种续约中，我们建议以我们的成就为基础 进一步催化研究以通过这些特定目的结束流行病：1）组装跨机构的， 跨学科的，包括社区的ERC-CFAR研究团队，以制定和实施新的策略 减少艾滋病毒传播，改善预防和治疗，促进持续的病毒抑制和辐射 艾滋病毒水库； 2）通过生物标志物的尖端服务来增加我们的研究的影响 以及先进的技术核心，行为和实施科学核心以及临床和翻译 科学核心； 3）为下一代艾滋病毒调查人员的心理，新兵成立了非HIV研究者 进行艾滋病毒研究，并在爱因斯坦，洛克菲勒和其他NIH资助的CUNY进行新的合作 中心，地区学术中心，我们的公共卫生部门和社区合作伙伴，以支持 创新的Ehe Agernda通过发展核心，当前的艾滋病毒和心理健康以及未来的SWG。